Turning Point reports positive data for tumor drug candidate
Turning Point Therapeutics (TPTX) reported positive preliminary data from its Phase 2 clinical trial TRIDENT-1. The trial is designed to assess the potential of repotrectinib in treating patients with ALK-, ROS1- or NTRK-3-mutation-positive solid tumors. The data cutoff date was July 10, 2020. The drug candidate was also found to be generally well-tolerated.
The early Phase 2 TRIDENT-1 dataset includes the first 39 treated patients who have had at least one post-baseline scan. A subsequent scan was done at least 28 days later to